
Lannett Company LCI
Quarterly report 2023-Q1
added 05-15-2023
Lannett Company EBITDA per Share 2011-2026 | LCI
Annual EBITDA per Share Lannett Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.52 | -4.81 | 1.97 | 4.57 | 6.26 | 6.66 | 6.32 | 6.48 | 2.79 | 0.877 | 0.447 | 0.142 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.66 | -4.81 | 2.35 |
Quarterly EBITDA per Share Lannett Company
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.84 | -0.24 | -0.17 | -1.42 | -1.67 | -1.55 | 0.04 | -1.43 | 0.22 | -5.35 | 0.37 | -4.76 | 0.37 | 0.59 | 0.58 | 1.13 | 0.58 | 1.12 | -8.7 | 1.73 | -8.7 | 1.42 | 1.47 | 2.01 | 1.47 | 1.08 | -0.16 | 1.69 | -0.16 | 0.9 | 1.47 | 1.06 | 1.47 | 1.9 | 1.57 | 1.94 | 1.57 | 0.76 | -0.31 | 0.82 | -0.31 | 0.2 | 0.19 | 0.27 | 0.19 | 0.05 | 0.1 | 0.12 | 0.1 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.01 | -8.7 | -0.249 |
EBITDA per Share of other stocks in the Drug manufacturers industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Adamis Pharmaceuticals Corporation
ADMP
|
-0.16 | - | 0.86 % | $ 117 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-0.32 | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
-9.17 | - | 10.11 % | $ 58.2 M | ||
|
Assertio Holdings
ASRT
|
1.32 | $ 18.02 | -2.12 % | $ 115 M | ||
|
Aerie Pharmaceuticals
AERI
|
-0.86 | - | - | $ 754 M | ||
|
Catalent
CTLT
|
-1.44 | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
-1.4 | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
6.31 | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
1.3 | - | - | $ 28.9 M | ||
|
Alimera Sciences
ALIM
|
0.27 | - | - | $ 142 M | ||
|
Athenex
ATNX
|
-10 | - | -23.39 % | $ 1.76 M | ||
|
Evoke Pharma
EVOK
|
-2.22 | - | - | $ 36.6 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-0.42 | - | - | $ 2.06 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
0.22 | $ 3.11 | -0.96 % | $ 43.7 M | ||
|
Cronos Group
CRON
|
-0.504 | $ 2.55 | 0.79 % | $ 1.33 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-10.3 | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-0.67 | - | 2.45 % | $ 38.1 M | ||
|
Bausch Health Companies
BHC
|
6.1 | $ 5.39 | 0.75 % | $ 1.97 B | ||
|
Harrow Health
HROW
|
0.87 | $ 37.29 | 1.52 % | $ 1.37 B | ||
|
Aurora Cannabis
ACB
|
-1.67 | $ 3.48 | 1.46 % | $ 86.3 M | ||
|
Canopy Growth Corporation
CGC
|
-0.89 | $ 1.09 | 4.81 % | $ 117 M | ||
|
Jupiter Wellness
JUPW
|
0.16 | - | - | $ 33.6 M | ||
|
Evolus
EOLS
|
-0.39 | $ 4.24 | 3.67 % | $ 273 M | ||
|
Emergent BioSolutions
EBS
|
-11.7 | $ 8.45 | 0.72 % | $ 433 M | ||
|
Neoleukin Therapeutics
NLTX
|
-4.7 | - | - | $ 193 M | ||
|
OrganiGram Holdings
OGI
|
-0.36 | $ 1.44 | 3.6 % | $ 402 M | ||
|
Organogenesis Holdings
ORGO
|
0.09 | $ 2.29 | -4.18 % | $ 302 M | ||
|
Pacira BioSciences
PCRX
|
0.12 | $ 23.82 | 2.45 % | $ 1.1 B | ||
|
PetIQ
PETQ
|
2.8 | - | 1.64 % | $ 400 M | ||
|
Sundial Growers
SNDL
|
-71 | $ 1.38 | 1.47 % | $ 3.37 M | ||
|
ProPhase Labs
PRPH
|
1.79 | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
-1.13 | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
0.05 | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
-1.5 | $ 7.61 | 8.56 % | $ 300 M | ||
|
SCYNEXIS
SCYX
|
-0.32 | $ 0.99 | -0.4 % | $ 49.4 M | ||
|
OptiNose
OPTN
|
-0.2 | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
-1.72 | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
-2.03 | $ 8.1 | 1.0 % | $ 709 M | ||
|
Tilray
TLRY
|
-2.22 | $ 6.72 | -0.44 % | $ 4.15 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
-2.88 | $ 2.41 | 5.24 % | $ 2.99 M | ||
|
Veru
VERU
|
-0.27 | $ 2.43 | -4.71 % | $ 328 M | ||
|
Viatris
VTRS
|
2.92 | $ 13.61 | 0.29 % | $ 16.3 B | ||
|
cbdMD
YCBD
|
-0.66 | $ 0.65 | -6.59 % | $ 2.8 M | ||
|
Zomedica Corp.
ZOM
|
-0.08 | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-0.82 | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
-0.07 | $ 0.93 | -0.98 % | $ 33.5 M | ||
|
Tricida
TCDA
|
-2.97 | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
-0.4 | $ 0.66 | 5.66 % | $ 2.83 M | ||
|
TherapeuticsMD
TXMD
|
-0.35 | $ 2.05 | - | $ 23.7 M |